After Exiting 2seventy, Chip Baird Took a 180 to Food Allergy With Newly Launched Poplar

Poplar Therapeutics is seeking a “step change” in the treatment of food allergy and other atopic conditions, with $95 million raised to date, including a $45 million series A extension that closed Tuesday.

Scroll to Top